Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

Market: Pharmaceuticals and Healthcare

Global, 133 pages report, published by GBI Research

Keywords : Neurodegenerative disorder, alzheimer’s disease, parkinson’s disease, huntington’s disease, amyotrophic lateral sclerosis, multiple sclerosis

Report ThumbnailDecember-2016
Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

Summary

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

The report focuses on five key indications within neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis. With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in amyotrophic lateral sclerosis and multiple sclerosis. This indicates the need for extensive R&D within this area.

Immunomodulators are the most effective and most common therapies used in neurodegenerative disorders. This class of compounds has been the most commercially successful in the past decade, particularly in the multiple sclerosis market, with many clinical trials underway for amyotrophic lateral sclerosis. The market for neurodegenerative disorders is largely accounted for by premium products, with generic products holding only a relatively small share. However, some generic products have been able to secure sizable market shares after the patent expiries of leading drugs. Glatopa (a generic version of Copaxone) recently entered the market and is expected to reach sales of $233m within the forecast period.

Although there is a high degree of failure and uncertainty within the R&D of neurodegenerative disorder drugs, the number of drugs in the pipeline is very high, at 1,494. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of molecules being developed as therapeutic agents within the neurodegenerative disorders pipeline. The market is expected to grow over the forecast period, which is attributed to the approval of new drugs, as well as the increasing aging population.

Scope

- Global revenues for the neurodegenerative disorders market are forecast to grow at a compound annual growth rate of 7.42%, from $27.2 billion in 2015 to $45 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The neurodegenerative disorders pipeline is large and diverse, and contains 1,494 products. How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action and molecule types are being trialed most commonly in pipeline products for the key indications?
- Which products will contribute most significantly to market growth, and which will achieve blockbuster status?
- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share set to change?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the neurodegenerative disorders market across each indication, in terms of dominant molecule types and targets, and key commercial assets and players
- Analyze the neurodegenerative disorders pipeline and stratify by stage of development, molecule type and molecular target, making use of a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the neurodegenerative disorders market, globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various neurodegenerative disorders
- Identify commercial opportunities in the neurodegenerative disorders deals landscape by analyzing trends in licensing and co-development deals
  • 1.2 List of Figures
  • Figure 1: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Alzheimer’s Disease (‘000), 2015-2022 24
  • Figure 2: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Parkinson’s Disease (‘000), 2015-2022 25
  • Figure 3: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Huntington’s Disease (‘000), 2015-2022 26
  • Figure 4: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Amyotrophic Lateral Sclerosis (‘000), 2015-2022 27
  • Figure 5: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Multiple Sclerosis (‘000), 2015-2022 28
  • Figure 6: Neurodegenerative Disorders, Global, Key Marketed Products and Approved Indications, 2016 35
  • Figure 7: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Tecfidera ($bn), 2013-2022 37
  • Figure 8: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Copaxone ($bn), 2006-2022 39
  • Figure 9: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Tysabri ($bn), 2006-2022 41
  • Figure 10: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Gilenya ($bn), 2011-2022 43
  • Figure 11: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Avonex ($bn), 2006-2022 44
  • Figure 12: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Plegridy ($bn), 2014-2022 46
  • Figure 13: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Namenda/Namenda XR ($bn), 2006-2022 47
  • Figure 14: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Nuplazid ($bn), 2016-2022 49
  • Figure 15: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Neurodegenerative Disorder by Stage of Development, Molecule Type and Program Type, 2016 51
  • Figure 16: Breakdown of Biologics in Neurodegenerative Disorders Pipeline, 2016 51
  • Figure 17: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Key Neurodegenerative Disorder Indications by Stage of Development, 2016 52
  • Figure 18: Neurodegenerative Disorders Therapeutics Market, Pipeline by Mechanism of Action (%), 2016 53
  • Figure 19: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Key Neurodegenerative Disorder Indications by Mechanism of Action, 2016 54
  • Figure 20: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016 55
  • Figure 21: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016 56
  • Figure 22: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 57
  • Figure 23: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 58
  • Figure 24: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016 59
  • Figure 25: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016 60
  • Figure 26: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016 61
  • Figure 27: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016 62
  • Figure 28: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016 63
  • Figure 29: Neurodegenerative disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2015 64
  • Figure 30: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016 65
  • Figure 31: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016 66
  • Figure 32: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development (patients), 2006-2016 67
  • Figure 33: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016 68
  • Figure 34: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2015 69
  • Figure 35: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016 70
  • Figure 36: Neurodegenerative Disorders, Global, Annual Revenue for Ocrelizumab ($bn), 2016-2022 71
  • Figure 37: Neurodegenerative Disorders, Global, Annual Revenue for Ozanimod ($bn), 2018-2022 73
  • Figure 38: Neurodegenerative Disorders, Global, Annual Revenue for Solanezumab ($bn), 2017-2022 74
  • Figure 39: Neurodegenerative Disorders, Global, Annual Revenue for Crenezumab ($m), 2017-2022 76
  • Figure 40: Neurodegenerative Disorders, Global, Annual Revenue for Tirasemtiv ($m), 2019-2022 77
  • Figure 41: Neurodegenerative Disorders, Global, Annual Revenue for CVT-301 ($m), 2018-2022 78
  • Figure 42: Neurodegenerative Disorder Therapeutics Market, Global, Market Size ($bn), 2015-2022 80
  • Figure 43: Neurodegenerative Disorders, Global, Annual Revenue for Key Products ($m), 2014-2022 82
  • Figure 44: Neurodegenerative Disorders, Global, Annual Revenue for Immunomodulators ($bn), 2015-2022 83
  • Figure 45: Neurodegenerative Disorders, Global, Annual Revenue for Neuromodulators ($bn), 2015-2022 84
  • Figure 46: Neurodegenerative Disorders, Global, Annual Revenue for Amyloid Inhibitors ($bn), 2015-2022 84
  • Figure 47: Neurodegenerative Disorders, Global, Annual Revenue for APP inhibitors ($m), 2015-2022 85
  • Figure 48: Neurodegenerative Disorders Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 86
  • Figure 49: Neurodegenerative Disorders, Global, Market Share by Company (%), 2015-2022 89
  • Figure 50: Neurodegenerative Disorders, Global, Companies by Compound Annual Growth Rate (%), 2014-2022 90
  • Figure 51: Neurodegenerative Disorders, Global, Revenue by Product Type, 2015-2022 91
  • Figure 52: Neurodegenerative Disorders, Global, Biogen Annual Revenue ($bn), 2015-2022 92
  • Figure 53: Neurodegenerative Disorders, Global, Novartis Annual Revenue ($bn), 2015-2022 93
  • Figure 54: Neurodegenerative Disorders, Global, Roche Annual Revenue ($bn), 2015-2022 94
  • Figure 55: Neurodegenerative Disorders, Global, Sanofi Annual Revenue ($bn), 2015-2022 95
  • Figure 56: Neurodegenerative Disorders, Global, Teva Annual Revenue ($bn), 2015-2022 96
  • Figure 57: Neurodegenerative Disorders, Global, Acadia Annual Revenue ($bn), 2015-2022 97
  • Figure 58: Neurodegenerative Disorders, Global, AbbVie Annual Revenue ($m), 2015-2022 98
  • Figure 59: Neurodegenerative Disorders, Global, Eli Lilly Annual Revenue ($m), 2015-2022 99
  • Figure 60: Neurodegenerative Disorders, Global, Celgene Annual Revenue ($m), 2015-2022 100
  • Figure 61: Neurodegenerative Disorders, Global, Lundbeck Annual Revenue ($m), 2015-2022 101
  • Figure 62: Neurodegenerative Disorders, Global, Companies by Type, 2016 102
  • Figure 63: Neurodegenerative Disorders, Global, High-Activity and Late-Stage Pipeline Developers by Level of Neurodegenerative Disorders, 2016 103
  • Figure 64: Neurodegenerative Disorders, Global, Proportion of Total Company Revenue Attributed to Neurodegenerative Disorders, 2015-2022 104
  • Figure 65: Neurodegenerative Disorders, Global, Licensing Deals, 2006-2016 106
  • Figure 66: Neurodegenerative Disorders, Global, Licensing Deals by Indication and Value, 2006-2016 107
  • Figure 67: Neurodegenerative Disorders, Global, Licensing Deals, 2006-2016 108
  • Figure 68: Neurodegenerative Disorders, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016 109
  • Figure 69: Neurodegenerative Disorders, Global, Co-development Deals, 2006-2016 114
  • Figure 70: Neurodegenerative Disorders, Global, Co-development Deals by Indication and Value, 2006-2016 115
  • Figure 71: Neurodegenerative Disorders, Global, Co-development Deals, 2006-2016 116
  • Figure 72: Neurodegenerative Disorders, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016 117
  • 1.1 List of Tables
  • Table 1: Neurodegenerative Disorders Therapeutics Market, Symptoms of AD, PD, HD, ALS and MS, 2016 14
  • Table 2: Neurodegenerative Disorders Therapeutics Market, Etiology of AD, PD, HD, ALS and MS, 2016 16
  • Table 3: Neurodegenerative Disorders , Global, Epidemiology of Neurodegenerative Disorders, 2016 23
  • Table 4: Neurodegenerative Disorders Therapeutics Market, Comorbidities Associated with AD, PD, HD, ALS and MS, 2016 29
  • Table 5: Neurodegenerative Disorders Therapeutics Market, Treatment Options Available for Parkinson’s Disease, 2016 31
  • Table 6: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Tecfidera, 2016 36
  • Table 7: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Copaxone, 2016 38
  • Table 8: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Tysabri, 2016 40
  • Table 9: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Gilenya, 2016 41
  • Table 10: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Avonex, 2016 43
  • Table 11: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Plegridy, 2016 45
  • Table 12: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Namenda/Namenda XR, 2016 47
  • Table 13: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Nuplazid, 2016 48
  • Table 14: Neurodegenerative Disorders, Global, Annual Revenue for key Products ($bn), 2015-2022 81
  • Table 15: Neurodegenerative Disorders, Global, Revenue by Company, 2015-2022 88
  • Table 16: Neurodegenerative Disorders, Global, Licensing Deals Valued above $100m, 2006-2016 110
  • Table 17: Neurodegenerative Disorders, Global, Co-development Deals Valued above $100m, 2006-2016 118
  • 1 Table of Contents
  • 1 Table of Contents 5
  • 1.1 List of Tables 7
  • 1.2 List of Figures 7
  • 2 Introduction 10
  • 2.1 Therapy Area Introduction 10
  • 2.1.1 Alzheimer’s Disease 10
  • 2.1.2 Parkinson’s Disease 11
  • 2.1.3 Huntington’s Disease 11
  • 2.1.4 Amyotrophic Lateral Sclerosis 12
  • 2.1.5 Multiple Sclerosis 13
  • 2.2 Symptoms 14
  • 2.3 Etiology and Pathophysiology 15
  • 2.3.1 Pathophysiology 18
  • 2.4 Epidemiology Patterns: Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 22
  • 2.4.1 Alzheimer’s Disease 23
  • 2.4.2 Parkinson’s Disease 24
  • 2.4.3 Huntington’s Disease 25
  • 2.4.4 Amyotrophic Lateral Sclerosis 26
  • 2.4.5 Multiple Sclerosis 27
  • 2.5 Co-morbidities and Complications 28
  • 2.6 Treatment 29
  • 2.6.1 Alzheimer’s Disease 29
  • 2.6.2 Parkinson’s Disease 30
  • 2.6.3 Huntington’s Disease 33
  • 2.6.4 Amyotrophic Lateral Sclerosis 33
  • 2.6.5 Multiple Sclerosis 33
  • 3 Key Marketed Products 35
  • 3.1 Overview 35
  • 3.2 Tecfidera (dimethyl fumarate) - Biogen 35
  • 3.3 Copaxone (glatiramer acetate) - Teva 37
  • 3.4 Tysabri (natalizumab) - Biogen 39
  • 3.5 Gilenya (fingolimod hydrochloride) - Novartis 41
  • 3.6 Avonex (interferon beta-1a) - Biogen 43
  • 3.7 Plegridy (peginterferon beta-1a) - Biogen 44
  • 3.8 Namenda/Memary/Ebixa/Axura/Namenda XR (memantine hydrochloride/memantine hydrochloride ER) - Merz Pharma/Lundbeck/Forest/Daiichi Sankyo 46
  • 3.9 Nuplazid (pimavanserin tartrate) - Acadia 48
  • 4 Pipeline Landscape Assessment 50
  • 4.1 Pipeline Development Landscape 50
  • 4.2 Molecular Targets in the Pipeline 53
  • 4.3 Clinical Trials 55
  • 4.3.1 Failure Rate 55
  • 4.3.2 Clinical Trial Duration 59
  • 4.3.3 Clinical Trial Size 63
  • 4.3.4 Aggregate Clinical Program Size 67
  • 4.4 Assessment of Key Pipeline Products 70
  • 4.4.1 Ocrelizumab - Roche 70
  • 4.4.2 Ozanimod - Celgene 72
  • 4.4.3 Solanezumab - Eli Lilly 73
  • 4.4.4 Crenezumab - Roche 74
  • 4.4.5 Tirasemtiv - Cytokinetics 76
  • 4.4.6 CVT-301 (Levodopa) - Acorda Therapeutics 78
  • 4.5 5.5 Conclusion 79
  • 5 Multi-scenario Market Forecast to 2022 80
  • 5.1 Overall Market Size 80
  • 5.2 Generic Penetration 82
  • 5.3 Revenue Forecast by Molecular Target 82
  • 5.3.1 Immunomodulators (interferon receptor/S1PR1/MHC II/IL-2 receptor/cells expressing B lymphocyte antigen CD20/glucocorticoid receptor) 83
  • 5.3.2 Neuromodulators (acetylcholinesterase/dopamine receptor/5HTA receptor) 83
  • 5.3.3 Amyloid Inhibitors (Amyloid Beta Inhibitors) 84
  • 5.3.4 APP inhibitors (BACE) 85
  • 6 Company Analysis and Positioning 86
  • 6.1 Revenue and Market Share Analysis by Company 87
  • 6.1.1 Biogen - Will the Patent Expiration of Tysabri Cause a Loss in Market Size? 92
  • 6.1.2 Novartis - Gradual Decline in Revenue due to Gilenya Patent Expiration 93
  • 6.1.3 Roche - Approval of Ocrelizumab to Drive Market Size 94
  • 6.1.4 Sanofi - Aubagio and Lemtrada to Become Blockbuster Drugs 95
  • 6.1.5 Teva - Gradual Decline in Revenue due to Patent Expiration of Products 96
  • 6.1.6 Acadia - Newly Approved Nuplazid Expected to Achieve Blockbuster Status in Forecast Period 97
  • 6.1.7 AbbVie - Pipeline Product Approval to Significantly Increase CAGR 98
  • 6.1.8 Eli Lilly - Solanezumab to Achieve Blockbuster Status following its Approval 99
  • 6.1.9 Celgene - Its First Product in Neurodegenerative Disorder Market to Reach Blockbuster Status in Forecast Period 100
  • 6.1.10 Lundbeck - Approval of Idalopirdine to Offset Loss in Revenue Caused by Patent Expiration of Azilect 101
  • 6.2 Company Landscape 102
  • 6.3 Marketed and Pipeline Portfolio Analysis 103
  • 7 Strategic Consolidations 105
  • 7.1 Licensing Deals 105
  • 7.1.1 Deals by Region, Year and Value 105
  • 7.1.2 Deals by Stage of Development and Value 107
  • 7.1.3 Deals by Molecule Type, Mechanism of Action and Value 108
  • 7.1.4 Table for Licensing Deals Valued above $100m 110
  • 7.2 Co-development Deals 113
  • 7.2.1 Deals by Region, Year and Value 113
  • 7.2.2 Deals by Stage of Development and Value 115
  • 7.2.3 Deals by Molecule Type, Mechanism of Action and Value 116
  • 7.2.4 Table for Co-development Deals Valued above $100m 118
  • 8 Appendix 120
  • 8.1 References 120
  • 8.2 Abbreviations 130
  • 8.3 Disease List 131
  • 8.4 Methodology 131
  • 8.4.1 Coverage 131
  • 8.4.2 Secondary Research 132
  • 8.4.3 Market Size and Revenue Forecasts 132
  • 8.4.4 Pipeline Analysis 132
  • 8.4.5 Competitive Landscape 133
  • 8.5 Contact Us 133
  • 8.6 Disclaimer 133
  • Global neurodegenerative drugs market set to hit $45 billion by 2022, says GBI Research

    The neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%, according to business intelligence provider GBI Research.

    The company’s latest report states that much of this growth is expected to occur between 2018 and 2022, due to the approval of many pipeline products within these years. Indeed, several late-stage products are expected to be highly commercially successful, including ocrelizumab, ozanimod, solanezumab, ITI-007 and RG-7412.

    Qaisrah Khalid, Analyst for GBI Research, explains: “There is a large pharmaceutical pipeline for neurodegenerative disorders, consisting of approximately 1,494 products in active development. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics, or repositioned from other indications – most of which are at Phase I. This indicates progress in terms of different molecules being developed as therapeutic agents within the neurodegenerative pipeline.”

    GBI Research also states that several key market players, such as Biogen, Novartis and Sanofi, are forecast to maintain their strong market shares throughout the forecast period, despite the fact that many of the impending patent expiries – especially that of Biogen’s Tysabri and Novartis’ Gilenya – will affect these companies directly.

    Khalid continues: “The revenue for the highest-selling product within the MS market – Copaxone (glatiramer acetate), marketed by Teva – is expected to decrease substantially following its 2014 patent expiry, from just over $4 billion in 2015 to $2.5 billion by 2022, due to competition from generics, such as Glatopa. Declining revenues from this and other drugs will lead to a significant drop in the neurodegenerative disorder market share for Teva.

    “On the other hand, the approval of ocrelizumab within the forecast period is anticipated to boost revenues for Roche, making it a major player in the market. As such, Roche is forecast to overtake the majority of currently leading companies in terms of total revenue.”

    - Comments provided by Qaisrah Khalid, Analyst for GBI Research.

    - Information based on GBI Research’s report: “Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments”.

    - This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

Related Products

GBI ResearchGlobal Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory TreatmentsProduct ThumbnailGlobal Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments, Industry Report available for $4995Product #: 631436
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved